Antoni Sicras-Mainar1, Aram Sicras-Navarro2, Beatriz Palacios3, Luis Varela3, Juan F Delgado4. 1. Health Economics and Outcomes Research, Atrys Health, Barcelona, Spain. Electronic address: ansicras@atryshealth.com. 2. Health Economics and Outcomes Research, Atrys Health, Barcelona, Spain. 3. Departamento Médico, AstraZeneca, Madrid, Spain. 4. Servicio de Cardiología, Hospital Universitario 12 de Octubre, Fundación Investigación i+12, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain; Centro de Investigación en Red en Enfermedades Cardiovasculares (CIBERCV), Spain.
Abstract
INTRODUCTION AND OBJECTIVES: To describe the epidemiology and treatment of a large contemporary cohort of patients with heart failure (HF). METHODS: Observational, retrospective, population-based study using the BIG-PAC database, which includes people aged ≥ 18 years seeking care for HF between 2017 and 2019. The main variables were the prevalence/annual incidence rate, comorbidities, clinical variables, and medication administered. RESULTS: We identified 19 762 patients with HF from a total of 1 189 003 persons seeking medical attention from 2017 to 2019 (2019: mean age, 78.3 years; 53.0% men). Distribution by type of left ventricular ejection fraction (LVEF) was as follows: 51.7% reduced, 40.2% preserved, and 8.1% mid-range. In 2019, the prevalence was 1.89% (95%CI, 1.70-2.08), with an incidence rate of 2.78 new cases per 1000 persons/y. No statistically significant differences were observed in prevalence and/or incidence from 2017 to 2019. Among patients with HF with reduced ejection fraction (HFrEF), 64% received beta-blockers, 80.5% angiotensin-converting enzyme inhibitor/angiotensin receptor blockers or sacubitril-valsartan, and 29.8% an aldosterone antagonist. In addition, from the diagnosis (baseline) to 24 months of follow-up, there was discreet treatment optimization, which was notable in the first 3 to 6 months. CONCLUSIONS: Epidemiological data on HF remained stable during the study period, with a lower prevalence than that reported in non-population-based studies. There is wide room for improvement in the optimization of medical treatment of HFrEF.
INTRODUCTION AND OBJECTIVES: To describe the epidemiology and treatment of a large contemporary cohort of patients with heart failure (HF). METHODS: Observational, retrospective, population-based study using the BIG-PAC database, which includes people aged ≥ 18 years seeking care for HF between 2017 and 2019. The main variables were the prevalence/annual incidence rate, comorbidities, clinical variables, and medication administered. RESULTS: We identified 19 762 patients with HF from a total of 1 189 003 persons seeking medical attention from 2017 to 2019 (2019: mean age, 78.3 years; 53.0% men). Distribution by type of left ventricular ejection fraction (LVEF) was as follows: 51.7% reduced, 40.2% preserved, and 8.1% mid-range. In 2019, the prevalence was 1.89% (95%CI, 1.70-2.08), with an incidence rate of 2.78 new cases per 1000 persons/y. No statistically significant differences were observed in prevalence and/or incidence from 2017 to 2019. Among patients with HF with reduced ejection fraction (HFrEF), 64% received beta-blockers, 80.5% angiotensin-converting enzyme inhibitor/angiotensin receptor blockers or sacubitril-valsartan, and 29.8% an aldosterone antagonist. In addition, from the diagnosis (baseline) to 24 months of follow-up, there was discreet treatment optimization, which was notable in the first 3 to 6 months. CONCLUSIONS: Epidemiological data on HF remained stable during the study period, with a lower prevalence than that reported in non-population-based studies. There is wide room for improvement in the optimization of medical treatment of HFrEF.
Authors: Juan F Delgado-Jiménez; Javier Segovia-Cubero; Luis Almenar-Bonet; Javier de Juan-Bagudá; Antonio Lara-Padrón; José Manuel García-Pinilla; Juan Luis Bonilla-Palomas; Silvia López-Fernández; Sonia Mirabet-Pérez; Inés Gómez-Otero; Antonio Castro-Fernández; Beatriz Díaz-Molina; Josebe Goirigolzarri-Artaza; Luis Miguel Rincón-Díaz; Domingo Andrés Pascual-Figal; Manuel Anguita-Sánchez; Javier Muñiz; María G Crespo-Leiro Journal: J Clin Med Date: 2022-02-22 Impact factor: 4.241
Authors: Sara Pérez-Herrero; Noel Lorenzo-Villalba; Elena Urbano; Beatriz Sánchez-Sauce; Fernando Aguilar-Rodríguez; Máximo Bernabeu-Wittel; Rocio Garcia-Alonso; Llanos Soler-Rangel; Francisco Trapiello-Valbuena; Alejandra Garcia-García; Jose Manuel Casas-Rojo; Luis Beltrán-Romero; Lucia De Jorge-Huerta; Juan Igor Molina-Puente; Emmanuel Andrès; Rosario Iguarán-Bermúdez; Manuel Méndez-Bailón Journal: J Clin Med Date: 2022-08-05 Impact factor: 4.964
Authors: Carlos Escobar; Beatriz Palacios; Luis Varela; Martín Gutiérrez; Mai Duong; Hungta Chen; Nahila Justo; Javier Cid-Ruzafa; Ignacio Hernández; Phillip R Hunt; Juan F Delgado Journal: J Clin Med Date: 2022-09-02 Impact factor: 4.964
Authors: Carlos Escobar; Beatriz Palacios; Luis Varela; Martín Gutiérrez; Mai Duong; Hungta Chen; Nahila Justo; Javier Cid-Ruzafa; Ignacio Hernández; Phillip R Hunt; Juan F Delgado Journal: BMC Health Serv Res Date: 2022-10-08 Impact factor: 2.908